The New England journal of medicine, 2022-03, Vol.386 (9), p.837-846
2022
Details
- Autor(en) / Beteiligte
- Titel
- Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants
- Ist Teil von
- The New England journal of medicine, 2022-03, Vol.386 (9), p.837-846
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2022
- Link zum Volltext
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Nirsevimab is a monoclonal antibody to the RSV fusion protein that has an extended half-life. In this clinical trial, a single dose of nirsevimab resulted in a significantly lower incidence of medically attended RSV-associated lower respiratory tract infection than that with placebo.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2110275Titel-ID: cdi_proquest_miscellaneous_2635476741
- Format
- –
- Schlagworte
- Antibodies, Monoclonal, Humanized - administration & dosage, Antibodies, Monoclonal, Humanized - adverse effects, Antibodies, Monoclonal, Humanized - therapeutic use, Antiviral Agents - administration & dosage, Antiviral Agents - adverse effects, Antiviral Agents - therapeutic use, Cardiovascular disease, Care and treatment, Childhood Diseases, COVID-19, Drug Administration Schedule, Female, Fusion protein, Gestational age, Health aspects, Humans, Infant, Infant, Newborn, Infant, Premature, Infant, Premature, Diseases - prevention & control, Infants, Infections, Infectious Disease, Injection, Injections, Intramuscular, Kaplan-Meier Estimate, Male, Monoclonal antibodies, Neonatology, Newborn babies, Pediatrics, Pharmacokinetics, Placebos, Population, Prevention, Respiratory diseases, Respiratory syncytial virus, Respiratory syncytial virus infection, Respiratory Syncytial Virus Infections - prevention & control, Respiratory tract diseases, Testing, Viral Infections, Vitamin E